RNAseq analysis of IAV-infected AECs and AMs with and without TrkA inhibition. by Vikram Verma (13822961)

Ameliorative effect of nicotine exposure on insulin resistance is accompanied by decreased cardiac glycogen synthase kinase-3 and plasminogen activator inhibitor-1 during oral oest... by Olugbenga S. Michael (4410424)

“…<p><b>Context:</b> Cigarette smoking is considered to be a major risk factor for the development of diabetes and cardiovascular disease. …”

Social interaction of <i>Cdkl5</i> -/Y mice is uniquely altered. by Kosuke Okuda (5150393)

“…<i>Cdkl5</i> -/Y mice show a significant increase in the total duration of contacts (A), a significant increase in the mean duration per contact (B), a significant decrease in the number of contacts (C), a significant decrease in the total duration of active contacts (D), and a significant decrease in the distance traveled (E). …”

Synthesis and Properties of the Heterospin (<i>S</i>₁ = <i>S</i>₂ = ¹/₂) Radical-Ion Salt Bis(mesitylene)molybdenum(I) [1,2,5]Thiadiazol... by Nikolay A. Pushkarevsky (1565458)

“…Low-temperature interaction of [1,2,5]­thiadiazolo­[3,4-<i>c</i>]­[1,2,5]­thiadiazole (<b>1</b>) with MoMes₂ (Mes = mesitylene/1,3,5-trimethylbenzene) in tetrahydrofuran gave the heterospin (<i>S</i>₁ = <i>S</i>₂ = ¹/₂) radical-ion salt [MoMes₂]⁺[<b>1</b>]⁻ (<b>2</b>) whose structure was confirmed by single-crystal X-ray diffraction (XRD). …”

Exposure of HOB to chemotherapeutic agents or rTGF-β1 diminished the ability of HOB to support human embryonic stem cells and decreased pro-B cell interaction with HOB. by Stephanie L. Rellick (182765)

Schematic representation of possible intracellular 5-HT signaling pathways in chondrocytes. by Ayaka Hori (4597795)

“…Then, the phosphorylated ERK1/2 level is increased through both activation of PKCε and PKCζ; as a result, CCN2 production is decreased. Furthermore, independent of PKC, 5-HT may transmit a certain unknown signal to JNK, which also inhibits the CCN2 production in chondrocytes.…”

Datasheet1_Acquired von Willebrand syndrome (AVWS) type 2, characterized by decreased high molecular weight multimers, is common in children with severe pulmonary hypertension (PH)... by Ivonne Wieland (14112981)

“…Notably, 3 of 5 patients (60%) with normal VWF:Ac/VWF:Ag ratio >0.7 had abnormal VWF multimers, indicating AVWS type 2. …”

Inhibition of BCO1 promoter activity by dexamethasone. by Xiaoming Gong (19039)

Poly I:C fails to restore hepatic TRAIL⁺ NK cells after hepatectomy in CXCR3 KO mice. by Takuya Yano (415157)

Table 1_A national population-based study of mortality and risk factors in COVID-19-hospitalized patients in Spain (2020–2021).docx by José-Manuel Ramos-Rincón (10428656)

“…Hospitalization rates dropped from 697/100,000 people to 411/100,000, and in-hospital mortality (IHM) decreased from 16.2 to 11.5% (adjusted odds ratio [AOR]: 0.71, 95% CI: 0.70–0.73, p < 0.001). …”

Graphic representation of the relation between the mean values of alveolar volume, calculated by the quintile method, and those of the corresponding DLCO, in healthy individuals (p... by Renato Prediletto (86307)

“…</p><p></p> The alveolar volume does not show any remarkable change when related to the expired volume in healthy individuals (only 300 ml), at variance with those of COPD patients. In addition, DLCO decreases by 1.5 mmol/min/mmHg with respect to the slight changes of the alveolar volume in healthy individuals, whereas it increases by less than 1 mmol/min/mmHg for a total increase of 2.5 litres of alveolar volume in COPD patients from TLC to RV.…”

Reduction of the PPARγ/RXRα heterodimer binding to BCO1 promoter by dexamethasone. by Xiaoming Gong (19039)

(A) Activity of SOD under B stress; (B) Activity of POD under B stress; (C) Activity of CAT under B stress; (D) Activity of APX under B stress; (E) Content of MDA under B stress ac... by Qiang Li (8118)

Passive transfer of humanized anti-NS1 mAb 33D2 into DENV-inoculated mice decreases viral titer and NS1 level in mouse sera. by Sen-Mao Tien (12481273)

Table_2_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

The relationship between diabetes and colorectal cancer prognosis: A meta-analysis based on the cohort studies by Bo Zhu (118038)

“…</p><p>Results</p><p>The results found that compared to patients without diabetes, patients with diabetes will have a 5-year shorter survival in colorectal, colon and rectal cancer, with a 18%, 19% and 16% decreased in overall survival respectively. …”

Image_2_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.tif by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Table_4_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Table_1_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”

Image_1_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.tif by Xiao-yang Gong (13103400)

“…</p>Results<p>To the best to our knowledge, we present for the first time an overview of the genomic mutation spectrum of early-stage laryngeal cancers. A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”